Toripalimab-tpzi

DRUG3 trials

Sponsors

Georgetown University, Massachusetts General Hospital, Metaclipse Therapeutics Corporation

Conditions

HNSCCHead and Neck CancerHead and Neck Cancer Squamous Cell CarcinomaNeoplasm Recurrence, LocalOvarian Cancer Stage 3Ovarian Cancer Stage IIIOvarian Cancer Stage IVRecurrent Head and Neck Squamous Cell Carcinoma

Phase 1

TMV Vaccine Alone or With Toripalimab-tpzi for Recurrent Head and Neck Squamous Cell Carcinoma

RecruitingNCT07898124

Metaclipse Therapeutics CorporationHNSCC, Neoplasm Recurrence, Local, Recurrent Head and Neck Squamous Cell Carcinoma +2

Start: 2026-10-01End: 2031-02-28Target: 30Updated: 2026-10-27

Phase 2

A Combination Therapy Strategy to Prevent Anti-PD-1 Therapy Resistance in Metastatic Ovarian Cancer Patients

WithdrawnNCT05479045

Georgetown UniversityOvarian Cancer Stage 3, Ovarian Cancer Stage III, Ovarian Cancer Stage IV

Start: 2026-09-01End: 2028-11-01Updated: 2026-10-09

PDT For Induction Therapy For Head And Neck Cancer

RecruitingNCT07214987

Massachusetts General HospitalHead and Neck Cancer, Head and Neck Cancer Squamous Cell Carcinoma, Squamous Cell Carcinoma

Start: 2026-03-09End: 2029-09-01Target: 26Updated: 2026-10-19